Treatment of refractory & recurrent ovarian cancer. AIDS-related Kaposi's sarcoma (KS) in patients w/ low CD4 counts & extensive mucocutaneous or visceral disease, metastatic breast cancer. In combination w/ bortezomib for refractory & relapsed multiple myeloma.